Dr. Tatiana Tiago, Product Manager at Creoptix, discusses the challenges and opportunities in drug screening with an expert panel.

Watch the video to hear:

• An introduction to Creoptix WAVEsystem and Grating Coupled Interferometry (GCI) technology, a powerful Surface Plasmon Resonance (SPR)-based technology (Dr. Tatiana Tiago)
• An overview of Domainex and its role in supporting drug discovery (Dr. Tom Mander, CEO at Domainex)
• An insight into how the GCI technology is helping Domainex tackle fragment library screening, hit identification/expansion and lead optimisation (Dr. Trevor Askwith, Head of Assay Biology at Domainex)